Boniva Articles
FDA approves first generics of Roche osteo drug Boniva
20 March 2012
As US District Court dismisses patent use code counterclaim, all eyes move to the Supreme Court Prandin case, says law firm
22 November 2011
USA’s FDA calls for label changes on bisphosphonates due to possible increased risk of thigh bone fracture
14 October 2010
One cheer for Pfizer’s Fablyn
26 February 2010
FDA finds no AF link for bisphosphonates
24 November 2008
Roche's 1st-half net profit sees downturn
28 July 2008
FDA warns: severe pain with bisphosphonates
14 January 2008
GSK posts solid results for 1st-qtr 2007 with a 14% EPS rise despite US generic pressure
30 April 2007
Roche 1st-qtr at top end of expectations
23 April 2007
Roche posts record 2006 net profits, boosted by cancer drugs
12 February 2007
Roche reports sales of $23.89B for first three qtrs of 2006, a 4.7% share of global market
23 October 2006
Monthly Boniva raises treatment compliance
25 September 2006
Trial subjects favor once-daily Bonviva
27 March 2006
P&G/Sanofi file suit against Roche/GSK
16 January 2006
FDA approves Roche and GSK's IV Boniva
16 January 2006
Stock Commentary - Europe
11 April 2005
Roche/GSK's Boniva approved in USA
4 April 2005
GlaxoSmithKline's R&D pipeline looks set to drive near-term growth
21 February 2005
US volume Rx sales rise 8.3% in 2004
21 February 2005
Roche/GSK's IV Boniva filed in USA
20 December 2004
Stock Commentary - Europe
20 December 2004
Roche/GSK file once-a-month Bonviva in EU
27 September 2004
Roche and GSK file for once-monthly Boniva
31 May 2004
Options for a P&G/Aventis link-up reviewed by broker Natexis
26 January 2004
Roche/GSK's Bonviva at a monthly dose
30 November 2003
Showing 1-37 of 37 articles
- 1
- Boehringer Ingelheim gets FDA warning letter on cGMP failures
- AstraZeneca's naloxegol meets endpoints; EMA validates Gilead's sofosbuvir MAA
- Italy's pharma market slump set to continue, warns GlobalData
- Is failure to adopt business process management putting the pharma industry at risk?
- Sanofi and Regeneron's dupilumab shows 87% reduction in risk of asthma exacerbations
